A Case Report of Pancreatic Cancer with Liver Metastasis Patient Treated with Integrative Cancer Treatment |
Ko, Eun-ju
(East West Cancer Center, Daejeon Korean Medicine Hospital of Daejeon University)
Myong, Ji-soo (East West Cancer Center, Daejeon Korean Medicine Hospital of Daejeon University) Kim, Jong-hee (East West Cancer Center, Daejeon Korean Medicine Hospital of Daejeon University) Park, Ji-hye (East West Cancer Center, Seoul Korean Medicine Hospital of Daejeon University) Park, So-jung (East West Cancer Center, Daejeon Korean Medicine Hospital of Daejeon University) Lee, Yeon-weol (East West Cancer Center, Daejeon Korean Medicine Hospital of Daejeon University) Yoo, Hwa-seung (East West Cancer Center, Daejeon Korean Medicine Hospital of Daejeon University) |
1 | R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2020, CA: a cancer journal for clinicians 70:7-30, 2020. DOI |
2 | Roe, J. S. et al. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Cell. 170:875-888 e820, 2017. DOI |
3 | Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 395:2008-2020, 2020. DOI |
4 | Leonhardt CS, Traub B, Hackert T, Klaiber U, Strobel O, Buchler MW, et al. Adjuvant and neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma. J Pancreatol. 3:1-11, 2020. DOI |
5 | Siegel, R.L. et al. Cancer statistics, 2017. CA Cancer J. Clin. 67:7-30, 2017. DOI |
6 | Park BK, Yoo HS, Lee YW, Han SS, Cho JH, Son CG, Cho CK. Retrospective cohort analysis for lung cancer patients treated with Wheel Balance Therapy (WBT). Korean J Orient Int Med. 19(2):45-56, 2009. |
7 | National Cancer Institute. Common Terminology Criteria for Adverse Events(CTCAE) v.5.0, 2017. Available from https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_5.0/. |
8 | Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021. |
9 | Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 71(1):7-33, 2021. DOI |
10 | Walter, F. M. et al. Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): A prospective cohort study. Lancet Gastroenterol. Hepatol. 1, 298-306, 2016. DOI |
11 | Ryan DP, Hong TS, Bardeesy N. Pancreatic Adenocarcinoma. N Engl J Med. 371:1039-1049, 2014. DOI |
12 | Sriramulu Elluru, Jean-Paul Duong Van Huyen, Sandrine Delignat, Fabienne Prost, Jagadeesh Bayry, Michel D. Kazatchkine, Srini V. Kaveri, Arzneimittelforschung. 56(6):461-466, 2006 DOI |
13 | D.V. Catenacci, M.R. Junttila, T. Karrison, N. Bahary, M.N. Horiba, S.R. Nattam, R. Marsh, J. Wallace, M. Kozloff, L. Rajdev, D. Cohen, J. Wade, B. Sleckman, H. J. Lenz, P. Stiff, P. Kumar, P. Xu, L. Henderson, N. Takebe, R. Salgia, X. Wang, W. M. Stadler, F.J. de Sauvage, H.L. Kindler, Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer, J. Clin. Oncol. 33:4284-4292, 2015. DOI |
14 | Saad AM, Turk T, Al-Husseini MJ, Abdel-Rahman O. Trends in pancre-atic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. BMC Cancer. 18:688, 2018. DOI |
15 | Y. Miyasaka, T. Ohtsuka, R. Kimura, R. Matsuda, Y. Mori, K. Nakata, D. Kakihara, N. Fujimori, T. Ohno, Y. Oda, M. Nakamura, Neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel for borderline resectable pancreatic cancer potentially improves survival and facilitates surgery, Annals of Surgical Oncology. Springer New York LLC March. 1528-1534, 2019. |
16 | E. Giacomini, M. Severa, M. Cruciani, M.P. Etna, F. Rizzo, M. Pardini, C. Scagnolari, E. Garaci, E.M. Coccia, Dual effect of Thymosin α 1 on human monocyte-derived dendritic cell in vitro stimulated with viral and bacterial toll-like receptor agonists, Expert Opin. Biol. Ther. 15:S59-S70, 2015. |
17 | Zee J. Heating the patient: a promising approach. Ann Oncol 13(8):1173-1184, 2002. DOI |
18 | Schwartz LH, Litie' re S, de Vries E, et al: RECIST 1.1: Update and clarification-From the RECIST committee. Eur J Cancer 62:132-137, 2016 DOI |
19 | Zhao T, Ren H, Jia L, Chen J, Xin W, Yan F, et al. Inhibition of HIF-1 by PX-478 enhances the anti-tumor effect of gemcitabineby inducing immunogenic cell death in pancreatic ductal ade-nocarcinoma. Oncotarget. 6(4):2250-2262, 2015. DOI |
20 | Renia M, Bonettoa E, Cordio S, Passoni P, Carlo Milandri C, Cereda S, et al. Quality of life assessment in advanced pancreatic adenocarcinoma: results from a Phase III randomized trial. Pancreatology. 6(5):454-463, 2006. DOI |
21 | Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69:7-34, 2019. DOI |
22 | Makohon-Moore, A. P. et al. Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nat. Genet. 49:358-366, 2017. DOI |
23 | Joo EJ, Chun J, Ha YW, Ko HJ, Xu MY and Kim YS: Novel roles of ginsenoside Rg3 in apoptosis through downregulation of epidermal growth factor receptor. Chem Biol Interact. 233:25-34, 2015. DOI |
24 | Crawford HC, Pasca di Magliano M, Banerjee S. Signaling Networks That Control Cellular Plasticity in Pancreatic Tumorigenesis, Progression, and Metastasis. Gastroenterology. 156:2073-2084, 2019. DOI |
25 | United States National Cancer Institute. Pancreatic cancer: statistics. https://www.cancer.net/cancer-types/pancreatic-cancer/statistics, 2018. |